BioMarin Pharmaceutical Inc.
BMRN
$60.43
$1.903.25%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -18.26% | 61.47% | 156.15% | 154.99% | 154.62% |
| Total Depreciation and Amortization | -25.17% | -17.01% | -21.73% | -13.45% | -7.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 160.65% | 134.70% | 63.19% | 47.28% | 18.85% |
| Change in Net Operating Assets | -35.70% | 7.64% | -27.50% | 10.57% | 35.70% |
| Cash from Operations | 44.54% | 120.40% | 133.16% | 149.95% | 259.69% |
| Capital Expenditure | -20.62% | 13.67% | 26.73% | 22.63% | 11.65% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -111.72% | -20.33% | 43.60% | 6,816.65% | 1,624.87% |
| Cash from Investing | -403.49% | -5,958.02% | 156.25% | 228.30% | 222.70% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | -30,374.43% | -48,915.29% | -- |
| Issuance of Common Stock | -70.66% | -72.29% | -63.49% | -24.02% | -28.95% |
| Repurchase of Common Stock | 27.84% | 24.03% | 17.67% | 11.30% | -1.63% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 72.02% | 96.99% | -32.86% | -34.66% | 72.99% |
| Cash from Financing | 91.95% | 91.77% | -2,580.95% | -2,414.36% | -2,711.17% |
| Foreign Exchange rate Adjustments | -152.19% | 6.43% | -237.20% | -50.53% | 269.27% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 96.49% | 622.58% | -13.00% | 80.81% | 513.53% |